Sanuwave’s dermaPACE technology shows positive results

17 October 2011 (Last Updated October 17th, 2011 03:30)

Sanuwave Health's dermaPACE extracorporeal shockwave technology has demonstrated superiority over hyperbaric oxygen therapy in increasing angiogenic and tissue regenerative molecular changes in diabetic foot ulcers, a study has revealed.

Sanuwave Health's dermaPACE extracorporeal shockwave technology has demonstrated superiority over hyperbaric oxygen therapy in increasing angiogenic and tissue regenerative molecular changes in diabetic foot ulcers, a study has revealed.

PACE delivers high-energy acoustic pressure waves in the shockwave spectrum to produce compressive and tensile stresses on cells and tissue structures, promoting angiogenic and positive inflammatory responses, and quickly initiating the healing cascade.

In the study, 39 patients were given dermaPACE procedures twice weekly for three weeks and 38 patients were given 90 minutes of hyperbaric oxygen therapy daily for 20 days.

The results showed that dermaPACE increased angiogenic and tissue regenerative molecular changes in diabetic foot ulcers, and that there were no significant increases for hyperbaric oxygen therapy.

dermaPACE treatment also demonstrated increases in vWF, VEGF, eNOS, PCNA and EGF expressions, plus a decrease in TUNEL expression.